Objectives: Since Exercise and Sports Science Australia (ESSA) first published its position statement on exercise guidelines for people with cancer, there has been exponential growth in research evaluating the role of exercise pre-, during and post-cancer treatment. Design and Methods: The purpose of this report is to use the current scientific evidence, alongside clinical experience and exercise science principles to update ESSA's position statement on cancer-specific exercise prescription. Results: Reported in this position statement is a summary of the benefits accrued through exercise following a cancer diagnosis and the strengths and limitations of this evidence-base. An exercise prescription framework is then proposed to enable the application of cancer-specific considerations for individualisation, specificity, safety, feasibility and progression of exercise for all patients. Additional specific exercise prescription considerations are provided for the presence of haematological, musculoskeletal, systemic, cardiovascular, lymphatic, gastrointestinal, genitourinary and neurological disease-and treatment-related concerns, as well as presence of co-morbid chronic disease. Further, we also identify and discuss cancer-specific pragmatic issues and barriers requiring consideration for exercise prescription. Conclusions: While for the majority, multimodal, moderate to high intensity exercise will be appropriate, there is no set prescription and total weekly dosage that would be considered evidence-based for all cancer patients. Targeted exercise prescription, which includes the provision of behaviour change advice and support, is needed to ensure greatest benefit (as defined by the patient) in the short and longer term, with low risk of harm.
Introduction
In 2009, Exercise and Sports Science Australia (ESSA) published its first position statement on optimising cancer outcomes through exercise. 1 Since that time, the position statement has been used by health professionals to guide exercise prescription to cancer patients pre-, during and post-treatment, and has provided the foundation for continuing education courses in upskilling the workforce. In the past decade, cancer incidence in Australia has increased and cancer survival has continued to improve, 2 a rapidly expanding number of people living with a cancer diagnosis (>400,000 Australians are currently living with a cancer diagnosis in the previous five years). Further, there has been exponential growth in published high quality, randomised, controlled trials that have evaluated the effect of exercise on a range of cancer-related outcomes across the cancer trajectory, from diagnosis through to end of life. In recognition that Accredited Exercise Physiologists (AEPs) require and seek assistance in translating this evidence to their exercise prescription practice for people with cancer, who represent a growing population with diverse and cancer-specific health needs and priorities, we present a new ESSA exercise and cancer position statement. The purpose of this position statement is to: (1) provide a contemporary overview of the exercise and cancer evidence-base; and (2) present a framework for exercise prescription to patients, with cancer-specific considerations for individualisation, specificity, safety, feasibility and progression.
Evidence of exercise benefit following a cancer diagnosis
Benefits accrued through exercise during and beyond treatment for cancer have been extensively reviewed. Specifically, a recent publication reported that 140 meta-analyses have been published to date, with the majority (75%) showing statistically significant and clinically relevant benefit through exercise on a range of treatment-related side effects, physical, functional, and psychosocial outcomes. 3 ) identified more than 140 systematic reviews or meta-analyses and more than 90 nonsystematic reviews on new or emerging topics. There now exists evidence of varying strength on the safety, feasibility and/or efficacy of exercise throughout the cancer continuum in a range of cancers, including but not limited to, more common cancers such as breast, 4 prostate, 5 colorectal 6 and lung 7 cancer, as well as other cancers including haematological, 8 head and neck, 9 cancers of childhood and adolescence, 10 and gynaecological cancers, 11, 12 and less common cancers such as brain, 13 testicular 14 and pancreatic. 15 Some studies have specifically targeted patient cohorts with more advanced disease, 16, 17 providing initial evidence beyond patients with early-stage disease, generally considered 'well'.
Outcomes evaluated in trials have also broadened. There is now trial evidence (again of varying strength) regarding the potential positive effect of exercise for more contemporary treatmentrelated side effects, such as chemotherapy-induced peripheral neuropathy, 18 myalgia and arthralgias, 19, 20 lymphoedema (upper-and lower-limb), 21, 22 bone health, [23] [24] [25] sarcopenia 26, 27 and metabolic syndrome, 28 sleep quality, 29 cachexia, 30 cognitive impairment 31 and cardiotoxicity, 32, 33 as well as outcomes particularly relevant to the clinical and public health setting, such as treatment adherence or completion [34] [35] [36] and cost-effectiveness. 37 In the past five years, preliminary findings have also become available from phase 2 exploratory studies that have reported the effect of exercise on survival outcomes. [38] [39] [40] [41] Despite the exponential growth in the number and quality of clinical trials contributing to the broader evidence-base supporting exercise in oncology, there remains a preponderance of studies in the breast cancer setting and/or involving 'healthier, more active' cancer patients, 42 which is disproportionate to the characteristics of the wider cancer population. Further, there are varying levels of evidence in support of exercise as being safe, feasible and effective for various cancer cohorts, cancer subtypes, stages of disease and outcomes of interest. For example within the breast cancer setting, there is strong evidence to support exercise as being safe, feasible and effective at improving cardiorespiratory fitness, neuromuscular strength and quality of life during and post-breast cancer treatment (particularly for those diagnosed with early stage disease). 43 In contrast, the evidence to support exercise as being effective at improving survival outcomes for any cancer cohort is weak (findings come from underpowered, exploratory analyses). [38] [39] [40] [41] There is strong evidence that exercise leads to benefits when integrated during active treatment for a range of cancers, 43 but no evidence to suggest that the specific timing of an exercise session matters (e.g., evidence showing exercise during chemotherapy infusion is more or less effective at improving survival outcomes versus before or after infusion is lacking). Following a review of this literature, a forthcoming American College of Sports Medicine publication (to be published in Medicine and Science in Sports and Exercise, 2019) will provide exercise prescription guidelines specific to cancer-outcomes with a sufficient evidence-base to do so. The ESSA exercise and cancer guideline update presents a process that can guide the practical application of this evidence.
Recommended process for targeted, exercise prescription for cancer patients
When the evidence base for all cancer types, cancer-specific outcomes and different exercise prescriptions evaluated is reviewed in light of its strengths and limitations and applied in practice alongside generic exercise prescription principles, it provides a powerful foundation from which exercise can be used to improve the lives of those diagnosed with cancer. Fig. 1 , represents a recommended process that can guide individualised, evidence-based assessment, exercise prescription and follow-up to cancer patients (defined from herein as a person who has been diagnosed with cancer). It incorporates cancer-specific considerations to all aspects of patient care, including assessment and initial exercise prescription, as well as exercise principles of progressive overload, periodisation and autoregulation. Further, it incorporates the use of behaviour change strategies, education and monitoring, to ensure a patient-centred approach to the provision of care (specificity), while enabling patients to develop the necessary skills to ensure exercise can benefit their health in the longer term. The process is as follows: 1) Patient assessment, including patient and family health history (presence of comorbidities/additional chronic disease and related treatment); cancer diagnosis (previous and current); cancer treatment (previous, current and planned); risk, presence and severity of treatment-related toxicities (acute, persistent and late side effects); and physical activity and exercise history. 2) Determine health issues and prioritise contribution of these to risk of morbidity and/or mortality. Exercise prescription following cancer diagnosis typically seeks to influence any one or more of a range of outcomes, including but not limited to prevention or management of disease-and treatment-related toxicities. The exercise prescription must be focussed on ameliorating issues with greatest impact on health and survival. 3) Identify patient capacity and intervention suitability determined by considering economic, psychosocial and physiological constraints (including contraindications), accessibility, preferences, self-efficacy, barriers and facilitators to exercise, and potential benefit. 4) Prescribe exercise according to patient-driven exercise-related goals. 5) Reassessment and prescription modification by following points 1-4.
Screening tools and guidelines, such as the ESSA Adult Pre-Exercise Screening tool, 44 Physical Activity Readiness Questionnaire, 45 or the American College of Sports Medicine (ACSM) guidelines for exercise testing and prescription 46, 47 are useful for developing an initial health and risk profile for an individual. However, these tools are not designed to collect the necessary additional information required to enable safe and feasible exercise prescription for cancer patients. Instead, information needs to be collected on all issues specified in point 1 above, most of which can be sourced directly from the patient. However, patientderived information, particularly with respect to risk of developing acute, persistent or late treatment-related side effects, needs to be supplemented with information derived from reputable sources. The Australian Government online resource of cancer treatment protocols (https://www.eviq.org.au) may be useful in this regard. This information (point 1 above) could be supplemented with questionnaires typically used in cancer research and clinical management to measure and track changes in patient-reported outcomes including quality of life (e.g., Functional Assessment of Cancer Therapy (FACT) -General, 48 Patient-reported Outcomes Measurement Information System (PROMIS) 49 ), treatment-related side effects (e.g., PROMIS, 49 FACT-Breast 50 ) and exercise selfefficacy. 51 The initial assessment could also include a battery of physical/functional tests including assessments (or surrogate measures) of cardiorespiratory fitness, function, strength, balance, body composition and bone health.
Responses to screening tools, AEP-derived template of questions, externally-sourced treatment-related information, patientcompleted questionnaires, and results from physical assessment will allow an AEP and cancer patient to discuss point 2 above, and can aid the clinical judgement as to whether further testing, medical investigation or medical clearance is needed prior to commencing an exercise program. While there is no 'correct' or 'optimal' number and type of patient-reported or objectivelymeasured outcomes included in an initial assessment, patient test burden must be considered and limited. What must be measured are the minimum parameters necessary to prescribe a safe, feasible and effective exercise program. The inclusion of additional assessments should only occur when benefit of the information collected outweighs the burden of its assessment. Overall, research findings can only suggest potential components of the initial assessment; in the end, clinical judgement that is based on the patient's circumstances and exercise-related goals will dictate what is (and is not) assessed and why.
For a patient in the active treatment phase, 52 it is best practice to contact the treating clinician, informing them that exercise prescription is being integrated into cancer care and providing opportunity for comment or concerns. During treatment, the most appropriate clinician to liaise with will depend on the type and stage of cancer and treatment being received. For example, a urologist, medical oncologist or radiation oncologist may be the most appropriate clinician for those receiving treatment for prostate cancer, chemotherapy for colorectal cancer or radiation therapy for head and neck cancer, respectively. A general practitioner will likely be the most relevant clinician to liaise with during the post-treatment survivorship phase. Discussions with a patient during the initial assessment (point 1 above) will allow an AEP to identify the most appropriate clinician to communicate with and to establish consent to discuss patient information with this clinician.
The need for medical clearance prior to exercise testing and prescription for cancer patients is a topic of debate. Endorsing a blanket requirement for medical clearance for all cancer patients creates an additional barrier to the provision of exercise prescription. 53 Further, given the known harm of inactivity, only in rare circumstances would a targeted, exercise prescription be contraindicated. Yet the potential benefits of targeted exercise prescription prior, during and post-cancer treatment may not be recognised by all treating clinicians and may contribute to a situation whereby those patients most in need are the least likely to receive medical clearance (i.e., AEPs receive medical clearance and subsequent referral for only the 'well' cancer patient). However, requesting medical clearance can instigate communication between the AEP and a treating clinician, and the subsequent transfer of relevant exercise considerations that a patient may or may not be aware of. Therefore, the need for medical clearance should be considered on a case by case basis, but direct communication with at least one member of the treating team who can provide clinical guidance when needed 53 is recommended for all patients.
Following initial assessment (point 1 above), the next task is to assist a cancer patient to identify their specific health (psychological and/or physiological), quality of life and survival concerns (point 2 above) and to discuss potential benefit through exercise. Goals of exercise need to be prioritised according to what is of most value to the patient (e.g., symptom management, improving mood, minimising declines in cardiorespiratory fitness, reversing loss of muscle mass, survival), noting that some may prioritise long-term over short-term goals, psychosocial benefits over physiological or functional benefits, and that goals and priorities for all will likely change over time. A targeted exercise prescription is one that seeks to achieve these goals. Patient-factors that may influence adherence to this targeted prescription then need to be identified and discussed (point 3 above). This includes understanding patient circumstances (including current functional capacity, physical limitations/constraints) and preferences pertaining to type, frequency, intensity and duration, available finances to support exercise participation (which will influence degree to which the exercise is supervised and where), health literacy, exercise self-efficacy, ability to identify and problem solve exerciserelated barriers (which may be cancer-specific or general), the support network available to assist integrating exercise during and beyond cancer management, and motivation to achieve goals via exercise.
It will also be necessary to educate the patient about what constitutes realistic exercise-related goals (e.g., maintenance of function, slowing declines or improvements in function), with the patient's current cancer survivorship phase (pre-, during, posttreatment with treatment aim being cure, substantive remission or palliation 52 ) influencing expectations. Further, educating the patient about what exercise components will be necessary for achieving specific goals, particularly when patient exercise preferences fail to align with achieving their desired goal(s), will be relevant and important. In these instances, an AEP will need to help guide the patient in recognising what they are willing to do to achieve a goal (even if not enjoyable) versus what they are not willing to do. The final exercise prescription (point 4 above) represents one that considers exercise goals alongside health priorities, and ensures the patient is central to the discussion and decisions made.
Frequency and components of reassessment and prescription modification (point 5 above) will be influenced by the exercise prescription goals, whether the patient is in an active treatment phase, likelihood of changes in disease-and treatment-related toxicities that may influence or be influenced by the exercise prescription and access to AEP services. Of note, when the process of targeted exercise prescription is followed, AEPs can readily identify when a patient may benefit from referral to another allied health professional. For example, referral to a dietitian for those in need of nutritional advice, referral to supportive services (e.g., peer support connections) and health professionals including a psychologist, specialist oncology nurse or counsellor for those reporting concerns with fear of recurrence, or referral to a physiotherapist for those with acute or persistent musculoskeletal or neurological issues. Further, an AEP may play a pivotal role in referring a patient back to the treating team for clinical review of new or changing diseaseand treatment-related toxicities or side effects, which may or may not be associated with progression of disease.
While it is not possible to provide a specific exercise prescription based on an individual's diagnosis (and likely never will be), there are some general exercise prescription guidelines that will be appropriate for the majority of cancer patients, including children through to geriatric patients (Table 1) . Also, the growing body of evidence suggests beneficial prescription parameters for a number of side effects and treatment-related outcomes (Table 2) . In some cases, it will be appropriate to look to other disease states or chronic conditions for exercise principles and guidelines targeting similar outcomes (e.g., exercise and obesity guidelines for obese women receiving treatment for endometrial cancer; exercise and osteoporosis guidelines for osteopenic women receiving aromatase inhibitors for breast cancer or men receiving androgen deprivation therapy for prostate cancer; Table 2 ). However, appropriate caution is necessary given that the generalisability of safety, feasibility and efficacy findings among comorbidities is unknown. Further, as the benefits of exercise following cancer are better elucidated, it is prudent for exercise professionals to remain cognisant of potential harm through exercise, to educate patients about, and monitor presence of, contraindications, which largely relate to the presence of new or unusual changes to existing signs and symptoms (Table 2 ). Our approach of placing strong emphasis on using changes in signs and symptoms to guide exercise prescription (and exercise prescription modifications), while continuing to acknowledge the relative risks associated with abnormal haematological or other markers (e.g., oxygen saturation levels at rest), when known, is similar to that recently suggested by others. 54 3.1. Core components of exercise prescription: mode, intensity, frequency, duration, total exercise dosage, progression, periodisation and autoregulation Exercise mode: A multimodal exercise program, comprising aerobic and resistance (targeting large and specific muscle groups) exercise should be included in a patient's exercise prescription (Table 1) . However, the focus or emphasis of aerobic versus resistance exercise must be determined by a patient's needs and goals. For example, a woman with endometrial cancer advised to lose weight through dietary change, will need to increase emphasis on resistance training to ensure preservation of lean tissue during periods of weight loss, whereas a lung cancer patient who needs to improve cardiorespiratory fitness will need to increase emphasis on aerobic exercise. Exercise prescription emphasis requirements based on specific considerations are presented in Table 2 . While there is cross-over in exercise benefit (i.e., resistance exercise can produce a cardiorespiratory adaptation and aerobic exercise can produce a neuromuscular strength and endurance adaptation in cancer patients 55, 56 ), the magnitude of benefit will be influenced by training specificity. 56 As such, it is appropriate to consider patient preferences and resources when prescribing exercise mode, particularly during the early stages of exercise prescription in deconditioned patients. However, a patient also needs to be educated with respect to optimal exercise mode for achieving their defined exercise goals. Further, the specific modes chosen within aerobic and resistance exercise (e.g., water-based exercise versus use of ergometers versus walking, or free-weights versus machineweights versus therabands) should be influenced by cancer-specific factors (Table 2) , as well as patient preferences.
The inclusion of balance and flexibility training may improve the ability to undertake daily activities with reduced falls risk, discomfort, pain or concerns. 57 Yoga and Tai chi, which have been shown to improve quality of life and other cancer-related outcomes [58] [59] [60] (Table 2) , are potentially time efficient and beneficial means for incorporating balance training into exercise prescription for those in need. The inclusion of pelvic floor exercises is also particularly important for patients with or at high-risk of urinary and faecal incontinence (such as those treated for genitourinary, colorectal or gynaecological cancers), but likely appropriate for the majority of adult and geriatric patients. 61 Further, for highly deconditioned patients or patients nearing end of life, exercise prescription Table 1 Foundation exercise prescription guidelines for cancer patients.
Table 2
Acute or chronic cancer-related concerns requiring specific exercise prescription consideration a,b . emphasis may need to be placed on 'mobility' exercises (e.g., a range of specific upper-and lower-body exercises undertaken with low/no load) to accommodate and progress (when relevant) cardiovascular and respiratory function, neuromuscular strength and endurance, and flexibility capabilities. While focus should be given to targeted exercise prescription to address priority health issues, any kind of activity that a patient considers enjoyable or perceives as positively influencing cancerrelated outcomes (e.g., pain, quality of life) should be permitted or even encouraged. These activities (e.g., low-intensity yoga, Tai chi, meditation) can supplement the exercise prescription and will enhance adherence while providing additional physiological and psychological benefit. The exception to this recommendation is when a specific activity is considered contraindicated or risk of harm outweighs benefit (e.g., a brain cancer patient with balance concerns who wants to keep road cycling, a paediatric cancer patient with thrombocytopenia who wants to continue playing competitive rugby, an osteoporotic breast cancer patient who is taking aromatase inhibitors and wants to only do water-based exercise). When this is the case, patient education around benefit versus risk, and revisiting short and long term goals and priorities may help in steering the patient towards safe, feasible and effective exercise (e.g., advising use of a road bike on a wind-trainer for the brain cancer patient, encouraging participation in certain components of training but not game play for the paediatric cancer patient with thrombocytopenia; doing two water-based sessions per week, supplemented with two land-based strength sessions, including appropriate impact loading, per week for the osteoporotic breast cancer patient).
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Intensity: Patients should not be restricted to low-intensity exercise, nor is high-intensity exercise contraindicated for all. However, there will be times when low-intensity exercise is recommended (e.g., a patient with nausea that worsens with moderate intensity exercise) and when high intensity exercise may need to be avoided (e.g., immediate weeks post-surgery to avoid adversely influencing wound healing; presence of a blood clot related to a peripherally-inserted central catheter). Helping patients understand what constitutes low, moderate and high intensity exercise through the use of one or more tools, including rating of perceived exertion scale, heart rate and repetition maximum, is recommended. Self-reported methods of assessing intensity are considered particularly useful for those at risk of their heart rate response being influenced by treatment-induced cardiac changes or certain treatments (e.g., specific chemotherapeutic agents or HER2 targeting drugs). Self-reported methods are also considered useful for those experiencing 'good' and 'bad' days/weeks during an active treatment period. Further, helping patients understand what constitutes a normal physiological response to exercise and that they are in the best position to measure and monitor exertion (either by rating perceived exertion with or without objective measurement of heart rate) may improve exercise self-efficacy. 62 The intensity of exercise sessions, including whether interval training, impact loading, explosive dynamic training or other, is included should be determined by patient-driven factors (short and long term goals and interests) and cancer-specific factors (indications and contraindications, see Table 2 ). Evidence to support for example, high intensity interval training over moderate intensity continuous duration training for improving cardiorespiratory fitness in the longer term in cancer patients is currently unclear. 6, 63 However, for a patient who needs to improve fitness in a specific and short time frame (e.g., lung cancer patient with only 4 weeks prior to surgery), 64 there may need to be greater emphasis on undertaking exercise at high intensity.
Frequency and duration: Duration of any given exercise session will influence frequency of exercise bouts per day or week. For deconditioned patients, immediately post-surgery and/or for those with advanced stage disease, a starting exercise prescription may need to involve multiple short bouts (5-10 min duration) daily, to accumulate at least 20 min on any given day. As exercise capacity improves, progression towards longer sessions of at least 20 min duration on most days of the week is recommended. The 20 min cut-point being proposed (which has also been suggested by others previously 65 ) is not distinct and less duration per day may be more optimal for some patients (e.g., palliative patients with lung cancer). Instead this suggested cut-point reflects a pragmatic exercise duration whereby there is sufficient time for an exercise prescription that allows for a warm-up and cool-down component, sufficient disruption to cardiovascular, respiratory, neuromuscular, endocrine and immune homeostasis, and requires patients to actively plan/schedule their exercise, which in turn will aid longer term positive behaviour change. 66 Further, sessions of a minimum of 20-min duration could allow for sufficient weekly exercise dose while incorporating rest days (noting that rest days may be purposely scheduled into the exercise prescription due to pragmatic reasons or preferences, or be unplanned and occur due to the presence of one or more barriers).
Total exercise dosage: Intensity, frequency and duration combine to produce total dosage of exercise prescription over a defined period (e.g., week or month). Information gathered during the initial assessment, with particular attention to current and previous exercise, will enable an AEP to determine the appropriate starting exercise dosage. Erring on the side of caution (that is, prescribe less than more) in the initial phases of an exercise program, particularly for sedentary or deconditioned patients is recommended. Note, the targets promoted in physical activity guidelines for cancer patients (that is, >150 min of moderate intensity aerobic activity/>75 min of vigorous intensity aerobic activity plus 2 resistance exercise sessions, per week 67 ) may not represent an appropriate starting weekly exercise dosage for the majority of cancer patients, nor may they ever be achievable for specific patients. Studies involving women with either ovarian or metastatic breast cancer, and patients with either lung or pancreatic cancer, have specifically shown that while some may be able to achieve physical activity targets through exercise prescription at least some of the time, others were never able to achieve the target during the intervention period assessed. 30, 68, 69 Further, for some, the target may be unnecessary for accruing benefit (that is, benefits have been observed with lower dosages). 63 It will be important for patients to have an understanding of what constitutes their ideal weekly exercise dosage, and whether there is need for this dosage to be modified over time. The known dose-response relationship between exercise and physical and psychosocial outcomes is relevant for patients with cancer. Evidence from a large, systematic review of cohort studies evaluating the association between physical activity post-cancer and survival outcomes suggest that a weekly exercise dosage of around 150 min of moderate intensity (or equivalent volume) exercise per week represents the approximate dosage beyond which there may be diminishing benefits gained through undertaking higher dosages. 70 Nonetheless, there is some evidence to suggest that exercising at higher dosages may contribute to additional benefit in specific outcomes (e.g., fitness) for specific cohorts (e.g., patients with colon cancer). 71 While future research continues to improve our understanding about what constitutes minimum and maximum exercise dosage thresholds and for whom, it is reasonable to suggest that the majority of cancer survivors can safely undertake regular exercise, when commenced at conservative dosages, progressed gradually and appropriately modified for the presence of diseaseand treatment-related side effects and co-morbidities (Table 2) .
There is potential for benefit in the translation of research into periodisation to exercise prescription for cancer patients and several exercise oncology trials have incorporated various periodi- Table 3 Cancer-specific pragmatic issues and barriers requiring consideration for exercise prescription a .
sation models. 25, 72 Variation in volume and intensity across the week or within treatment cycles may stimulate greater physiological adaptation, and reduce boredom and risk of over-training. Further, periodised plans designed for optimal preparation for specific events, such as surgery or commencement of chemotherapy or radiation therapy, or to specifically address particular health issues should be considered. This may include sequential and cycling phases of emphasis on specific exercise modes such as resistance, aerobic, balance, and impact training. For example, the prescription of an extended phase of heavy resistance training before progressing to impact loading for maintaining bone density 25 ; planned emphasis on low intensity exercise when treatmentrelated symptoms are severe, and high intensity exercise when symptoms are mild; or emphasis on high load resistance training with water-based aerobic exercise during the initial weeks of exercise prescription for obese patients ( Table 2 ). In recognition that cancer patients experience marked fluctuations in exercise tolerance, capacity and self-efficacy, particularly during the active treatment phase, it is paramount to ensure flexibility is built into the exercise prescription. The prescription should enable patients to autoregulate session, weekly and monthly exercise dosage to accommodate 'good days/weeks' (whereby higher intensity and/or dosage may be undertaken) and 'bad days/weeks' (whereby reduced intensity and/or total dosage may be required to accommodate symptoms). Autoregulation can occur, when necessary, through modifications to mode, intensity, frequency, duration and/or total volume, guided by objective (e.g., heart rate, repetitions completed) and/or subjective (e.g., rating of perceived exertion) measures. Examples of the implementation of autoregulation in the oncology setting have been previously published for aerobic 73 and resistance 74 exercise. Overall, the total exercise dosage for a defined period should seek to achieve the desired physical and mental health benefit(s), while balancing risks of overtraining, maladaptation, suboptimal, low priority or unnecessary exercise.
Progression: How to approach the progression of exercise prescription will differ depending on whether the patient is in the pre-, during or post-treatment cancer survivorship phase. 52 For example, physical and physiological declines are typically observed during active treatment periods, and also during periods of disease progression. Consequently, an exercise intensity that is moderate in the early weeks of treatment may elicit a physiological response indicative of vigorous intensity exercise in the final weeks of chemotherapy or when the disease has advanced. As such, minimising regression of total exercise dosage and relative intensity, or maintaining these parameters throughout the treatment period could be considered appropriate progression and incorporates patient autoregulation as discussed above.
For those who have completed treatment with a curative intent, it is generally reasonable to expect that exercise can be progressed steadily through increased overall dosage via modifications to mode, frequency, intensity and duration. However, it remains important to consider the influence of any persistent treatment-related toxicities or co-morbidities and the risk of new issues, as well as the potential challenge of returning to daily activities including work, on how progression should and could be defined. For example, returning to domestic chores, paid employment, volunteering or family responsibilities after treatment, while maintaining previous weekly exercise dosage could be considered appropriate progression in the first 3-6 months posttreatment.
In all cases, the goal of progression is to facilitate and maintain benefits derived through exercise prescription in the short and longer term. Those who are already meeting or exceeding public health physical activity guidelines or conversely, those who are sedentary at time of diagnosis, may require more assistance with understanding what appropriate progression means and how it can be defined. For example, helping regular exercisers to modify expectations around physical response to exercise and to appreciate that minimising declines in function during active treatment periods is indicative of exercise benefit. For those who are sedentary at diagnosis, helping them to overcome fears associated with 'doing too much' and learning differences between treatment-related side effects and normal, short term physiological responses to exercise overload, will likely be an important part of provision of exercise prescription and support. However, it will also be necessary to help patients avoid overtraining, which may bring with it higher risk of physical stress, injury, and compromised immune function, with unknown effect on key cancer-outcomes, such as quality of life, treatment tolerance and effectiveness, and even survival. Signs of overtraining would include the presence of unusual symptoms, increased severity of symptoms and changes in symptom trajectory (e.g., persist longer than expected). Overall, a key role of an AEP is to assess the safety, feasibility and effect of specific exercises, weekly dosage and pace of progression within the framework of an individual cancer patient's risk profile and exercise-related goals.
Behaviour change strategies -an important component of exercise prescription
Through the implementation of behaviour change techniques including goal setting, self-monitoring, individualised education, exercise prescription and feedback, and social support, exercise adherence can be improved. 75 This, in turn, facilitates achieving predefined exercise goals. Identifying and helping a patient problem-solve general and cancer-specific issues and barriers to exercise also forms an essential component of exercise prescription (Table 3) . Finally, incorporating behaviour change strategies as part of the routine provision of exercise prescription will improve patient exercise self-efficacy, 76 and as such, provide them with the tools to use exercise to benefit their longer term health.
Education and monitoring of exercise prescription: In addition to standard exercise-related education topics, including appropriate clothing and footwear, hydration, and safe and appropriate use of equipment, a patient needs to be equipped to monitor the presence and severity of treatment-related side effects before, during and following exercise sessions and to be able to report on exercise response to the AEP. This represents important information that will enable appropriate modification to exercise prescription parameters for the purpose of autoregulation, periodisation and progression. Further, this information also allows for an adverse event or contraindication to exercise to be readily identified and managed accordingly. The presence of an unusual symptom or an unusual change to an existing symptom, rather than the presence of a persistent treatment-related side effect or symptom in itself, is more likely to represent an exercise contraindication. To detect the 'unusual', it is first necessary to have a clear understanding of what constitutes 'normal' or 'expected' for any given patient.
Conclusion
Overall, evidence supports that the implementation of exercise prescription brings with it reduced morbidity, improved function and quality of life, and potential for improved survival, with very low risk of harm. However, the strength of the evidence in support of exercise safety, feasibility and benefit is dependent on cancer type and outcome of interest. While for the majority, multimodal, moderate to high intensity exercise will be appropriate, there is no set prescription and total weekly dosage that would be considered evidence-based for all cancer patients. Appropriate exercise prescription for cancer patients needs to be targeted and individualised according to patient-and cancer-specific considerations.
